As healthcare systems worldwide prioritize patient safety and skin integrity, the global Medical Adhesive-Related Skin Injury (MARSI) treatment market is on a trajectory of steady expansion. Valued at USD 520.0 million in 2025, the market is projected to reach USD 931.2 million by 2035, growing at a compound annual growth rate (CAGR) of 6.0%. This growth underscores a shift toward advanced, atraumatic solutions that minimize skin trauma from medical adhesives, enhancing outcomes in hospitals, long-term care, and home settings.

MARSI, defined as skin trauma including epidermal stripping, friction, and tape-removal injuries from medical adhesives used in device securement and wound management, affects 10-30% of hospitalized or long-term care patients. With an aging global population and increasing prevalence of chronic conditions like diabetes and oncology cases, the demand for preventive and therapeutic interventions is intensifying. Industry leaders are responding with innovative protocols and products that not only treat but also prevent these injuries, reducing incidence by 30-50% through evidence-based strategies.

"Patient-centered care is at the heart of modern healthcare, and addressing MARSI is a critical step in reducing avoidable harm," said an industry expert familiar with wound care advancements. "By integrating gentle adhesives and barrier protectants into daily workflows, we're empowering clinicians to deliver safer, more effective treatments, particularly for vulnerable populations in ICUs, surgical wards, and home care."

Key growth drivers include heightened patient-safety priorities across acute, post-acute, and home-care environments. Global quality-improvement initiatives and accreditation frameworks are accelerating the adoption of MARSI-prevention bundles, clinician training, and nursing education. The rise in higher-acuity patients—such as those in oncology, diabetic, and ICU settings—necessitates atraumatic adhesives that protect fragile skin. Government-supported wound-care training and documentation further bolster this momentum, especially in emerging markets where hospital modernization is underway.

However, challenges persist. Cost sensitivity in resource-limited settings poses a restraint, as premium silicone-based dressings and barrier films can cost 30-60% more than traditional options. Variable clinician awareness, under-reporting of MARSI events, and reimbursement variability also hinder widespread investment in advanced technologies. Workflow adjustments in high-patient-load facilities add to the complexity, often prioritizing lowest-cost procurement over long-term benefits.

Opportunities abound for forward-thinking leaders. Integrating MARSI assessment tools, risk scoring, and removal training into clinical workflows can streamline operations and improve outcomes. Collaborations between wound-care specialists, dermatologists, and device manufacturers are fostering comprehensive prevention bundles and skin-health pathways. The expansion of home healthcare and postoperative tele-rehabilitation models demands gentle, extended-wear solutions that support independent patient care. In emerging regions like Asia Pacific and Latin America, hospital upgrades and patient-safety programs present untapped potential, with technological advancements in silicone-based adhesives, hydrophilic barriers, and antimicrobial-coated dressings leading the charge.

Market trends highlight a rapid shift toward standardized skin-integrity protocols and innovation in breathable protective films, polymer skin barriers, and gentle-release technologies. Improved vascular-access stabilization and dressing-removal practices are elevating bedside standards, while competitive pressures from manufacturers drive pricing shifts and material enhancements. The growth in remote monitoring further supports low-trauma adhesives, aligning with broader telehealth trends.

Segmentation reveals targeted areas of dominance. By product type, barrier films and sprays hold a 28% share in 2025, encompassing polymer barrier films, silicone sprays, and breathable coatings prized for their skin protection, moisture resistance, and device compatibility. Protective dressings follow at 22%, with adhesive removers and cleansers at 20%, topical therapeutics at 15%, and education and training also at 15%, emphasizing clinician competency.

In terms of application, hospital-based prevention programs command 45% of the market in 2025, fueled by high adhesive use in ICUs, surgical wards, oncology, and neonatal care. Treatment of MARSI cases accounts for 25%, while home-care prevention and long-term care each represent 15%, catering to fragile-skin populations in extended settings.

End-user analysis shows hospitals and wound clinics leading with 55% share, driven by acute care demands in oncology, NICU, ICU, and surgical environments. Long-term care facilities hold 20%, reflecting chronic device use among aging patients, with retail pharmacies at 15% for preventive products and homecare at 10% for post-discharge needs.

Regionally, North America stands out with mature adoption, led by the USA at a 6.5% CAGR, supported by strong clinical governance and patient-safety programs in key states like California, Texas, New York, and Florida. Europe follows at 5.5% CAGR, with Germany (5.4%, 21% share in 2025) excelling in advanced wound care around Berlin and Munich; France (5.3%, 18% share) focusing on oncology and geriatrics; and the UK (5.2%) leveraging NHS frameworks in London and Manchester. Western Europe's share grows from 22% to 24%, bolstered by nurse-training standards.

Asia Pacific exhibits the highest growth potential, with China at 7.0% CAGR amid hospital reforms in Beijing and Shanghai, and India at 7.5% through patient-safety initiatives in Delhi-NCR and Mumbai. Japan emphasizes quality-driven silicone dressings, while South Korea expands via global partnerships in Seoul and Busan. In Latin America, Brazil grows at 5.8% with modernization in São Paulo and Rio de Janeiro. The Middle East and Africa, including Saudi Arabia, GCC countries, Türkiye, and South Africa, focus on vascular-access and complication-prevention.

The competitive landscape is moderately consolidated, with specialized wound-care manufacturers at the forefront. Smith & Nephew leads through advanced silicone interfaces, polymer barriers, and evidence-aligned prevention frameworks, maintaining strong hospital relationships. ConvaTec and Mölnlycke emphasize clinical performance and material innovation, with Hollister expanding via ostomy expertise into protective films. Coloplast leverages hydrocolloid dressings for skin protection, while emerging regional players in Asia-Pacific and Latin America offer cost-efficient alternatives. Competition centers on biocompatibility, wear-time reliability, clinician education, and prevention pathways rather than mere pricing.

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates: https://www.futuremarketinsights.com/reports/brochure/rep-gb-29862

Request for Discount: https://www.futuremarketinsights.com/reports/sample/rep-gb-29862

Recent developments include the integration of MARSI protocols into vascular access, post-operative care, and infusion workflows across major hubs like China, India, Germany, Brazil, the USA, and the UK. Government-backed digital training programs are enhancing awareness, with partnerships between global manufacturers and local distributors tailoring services, especially in South Korea. Advances in antimicrobial barrier dressings and moisture-control technologies are particularly benefiting oncology, geriatric, and critical-care patients.

This market evolution positions industry leaders to capitalize on a nearly 1.8x expansion by 2035, covering over 40 countries and emphasizing dollar sales across products and settings. As healthcare continues to humanize its approach—focusing on gentle, effective care—the MARSI treatment market stands as a beacon of innovation, ensuring safer outcomes for patients worldwide.

Explore More Related Studies Published by FMI Research:

Otoacoustic Emissions Hearing Screener Market- https://www.futuremarketinsights.com/reports/otoacoustic-emissions-hearing-screener-market

Mobile Animal Inhalation Anesthesia Machine Market- https://www.futuremarketinsights.com/reports/mobile-animal-inhalation-anesthesia-machine-market

Cardiac Monitoring And Cardiac Rhythm Management Devices Market- https://www.futuremarketinsights.com/reports/cardiac-monitoring-and-cardiac-rhythm-management-devices-market

HSV Testing Market- https://www.futuremarketinsights.com/reports/hsv-testing-market

Hernia Protection Market- https://www.futuremarketinsights.com/reports/hernia-protection-market

 About Future Market Insights (FMI)

 Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Contact Us:    

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com